重塑一个银河糖代谢障碍的治疗景观
M Estela Rubio-Gozalbo1,2,3,4,5, E Naomi Vos1,2,3,4,5, Isabel Rivera6
1Department of Pediatrics, MosaKids Children's Hospital, Maastricht University Medical Centre, Maastricht, the Netherlands.
Journal of inherited metabolic disease
|February 15, 2025
概括
经典银血病 (CG) 治疗的进步探索了超越饮食的新疗法. 新兴的策略旨在恢复酶活性,减少有毒代谢物,并减轻长期并发症,以改善患者的治疗结果.
科学领域:
- 生物化学 生物化学
- 遗传学 是一个遗传学.
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 莱洛尔通路控制着银河糖代谢,而古典银河糖血病 (CG) 是由GALT基因变异引起的.
- 目前的治疗依赖于银河糖限制,管理新生儿危机,但不能预防认知缺陷和卵巢缺陷等长期并发症.
研究的目的:
- 审查经典银血病治疗策略的最新进展.
- 讨论针对GALT活性,代谢物积累和症状缓解的新兴治疗方法.
- 考虑重塑CG治疗模式的因素.
主要方法:
- 对CG的新兴治疗方式的审查.
- 分析包括基因疗法,酶替代和代谢途径调节在内的策略.
- 探索症状管理和饮食独立的新方法.
主要成果:
- 目前正在开发多种治疗途径,包括核酸疗法,酶替代和GALK1/阿尔多斯减少酶抑制剂.
- 策略还侧重于解决肌肉中性醇缺乏症,细胞压力和银河糖吸收问题.
- 正在研究新型干预措施,如合成生物药物和非侵入性脑刺激.
结论:
- 新兴疗法为CG提供了对终身饮食限制的有希望的替代方案.
- 解决酶功能,代谢途径和现有症状的多方面的方法至关重要.
- 个性化和早期干预是优化CG患者长期结果的关键.
相关概念视频
Glucose Transporters
22.4K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.4K
Oligosaccharide Assembly
2.8K
Protein glycosylation starts in the ER lumen and continues in the Golgi apparatus. Glycosyltransferases catalyze the addition of sugar molecules or glycosylation of proteins. Usually, these enzymes add sugars to the hydroxyl groups of selected serine or threonine residues to form O-linked glycans or the amino groups of asparagine residues to form N-linked glycans. Different positions on the same polypeptide chain can contain differently linked glycans.
Multiple sugar molecules that may or may...
Multiple sugar molecules that may or may...
2.8K
Overview of Carbohydrate Metabolism
682
Carbohydrate metabolism is a fundamental biochemical process that ensures a constant supply of energy to living cells. The most important carbohydrate is glucose, which can be broken down via glycolysis to enter into the Krebs cycle and eventually lead to the production of ATP through oxidative phosphorylation.
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
682
Glucagon-like Receptor Agonists
291
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
291
Hypoglycemia and Glucagon
149
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
149
Cystic Fibrosis: Management
139
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
139


